09:00-09:10 | Opening Ceremony |
Symposium 1 | ||||
---|---|---|---|---|
09:10 - 11:10 | Public health response to COVID-19 | Chair : | Dennis Dixon (USA), Kyong Ran Peck (Korea) |
|
S1-1 | Public health response to COVID-19: National perspective Hsien-Ho Lin ( National Taiwan University ), Taiwan |
|||
S1-2 | Public health response to COVID-19: Regional perspective Sharon Salmon ( World Health Organization ), Philippines |
|||
S1-3 | Public health response to COVID-19: Global perspective Maria Van Kerkhove ( WHO ), Switzerland |
|||
S1-4 | Strategies to flatten the curve: current evidence and practical pitfalls Paul Ananth Tambyah ( National University of Singapore ), Singapore |
Symposium 2 | ||||
---|---|---|---|---|
09:10 - 11:10 | Gram-negative bacteria | Chair : | David Paterson (Australia), Mi-Na Kim (Korea) |
|
S2-1 | Epidemiology and impact of carbapenem-resistant Acinetobacter and Pseudomonas Po-Ren Hsueh ( China Medical University, China Medical University Hospital ), Taiwan |
|||
S2-2 | Epidemiology and impact of carbapenem-resistant Enterobacteriaceae Anucha Apisarnthanarak ( Thammasat University Hospital ), Thailand |
|||
S2-3 | Emergence of intrinsic resistant Gram-negative bacteria with an environmental primary habitat José Luis Martínez ( Centro Nacional de Biotecnología. CSIC ), Spain |
|||
S2-4 | Antimicrobial therapy for carbapenem-resistant gram-negative bacteria Yohei Doi ( University of Pittsburgh ), USA |
Symposium 3 | ||||
---|---|---|---|---|
09:10 - 11:10 | How I treat difficult-to-treat infections (interactive) | Chair : | Jae-Hoon Song (Korea), Eun Hwa Choi (Korea) |
|
S3-1 | How I treat persistent S. aureus bacteremia Vance Fowler ( Duke Department of Medicine ), USA |
|||
S3-2 | How I treat vascular graft infections M. Rizwan Sohail ( Baylor College of Medicine ), USA |
|||
S3-3 | How I treat CMV infection in high-risk pediatric patients? Yae-Jean Kim ( Samsung Medical Center ), Korea |
Plenary Lecture 1 | ||||
---|---|---|---|---|
11:10 - 11:50 | Chair : | Dennis Dixon (USA) | ||
P-1 | Role of National Centre for Infectious Diseases during COVID-19 Yee Sin Leo ( National Centre for Infectious Diseases ), Singapore |
Plenary Lecture 2 | ||||
---|---|---|---|---|
11:50 - 12:30 | Chair : | Victor Lim (Malaysia) | ||
P-2 | Vaccines against SARS-CoV-2 Jerome H. Kim ( International Vaccine Institute ), Korea |
Plenary Lecture 3 | ||||
---|---|---|---|---|
15:10 - 15:50 | Chair : | Jae-Hoon Song (Korea) | ||
P-3 | Overview of the current status of antimicrobial resistance
David Livermore ( University of East Anglia ), UK |
Symposium 4 | ||||
---|---|---|---|---|
15:50 - 17:20 | Clinical management of COVID-19 | Chair : | Min Ja Kim (Korea) Shin-Woo Kim (Korea) |
|
S4-1 | Therapeutic options for COVID-19 Davey Smith ( University of California San Diego ), USA |
|||
S4-2 | Therapeutics for COVID-19 Yaseen Arabi ( King Abdulaziz Medical City, Ministry of National Guard Health Affairs ), Kingdom of Saudi Arabia |
|||
S4-3 | Long-term sequelae of COVID-19 Bin Cao ( National Clinical Research Center for Respiratory Diseases ), PR China |
Symposium 5 | ||||
---|---|---|---|---|
15:50 - 17:20 | Diagnostics/clinical microbiology | Chair : | David Livermore (UK), Mi-Na Kim (Korea) |
|
S5-1 | The future is here: rapid diagnosis of antimicrobial resistance Robin Patel ( Mayo Clinic ), USA |
|||
S5-2 | Next-generation sequencing for diagnosing infectious diseases John W. A. Rossen (Department of Medical Microbiology and Infection Prevention, University of Groningen), The Netherlands |
|||
S5-3 | How to combine novel techniques with stewardship: a real-world experience Tristan Timbrook, PharmD (bioMérieux; The University of Utah ), USA |
Symposium 6 | ||||
---|---|---|---|---|
15:50 - 17:20 | Antimicrobial stewardship | Chair : | Yee-Sin Leo (Singapore), Sungmin Kim (Korea) |
|
S6-1 | Shorter the better: current evidence for the shorter duration of antibiotic therapy David Paterson ( University of Queensland ), Australia |
|||
S6-2 | Capacity for antimicrobial stewardship in the Asia Pacific David Lye ( Tan Tock Seng Hospital ), Singapore |
|||
S6-3 | Antimicrobial stewardship during the COVID-19 pandemic Timothy Miles Rawson ( Imperial College London ), UK |
Symposium 7 | ||||
---|---|---|---|---|
09:00 - 11:00 | Pros and cons (interactive) | Chair : | Anucha Apisarnthanarak (Thailand), Hyunjoo Pai (Korea) |
|
S7-1 | Early oral transition for endocarditis Pro) Jose M. Miro ( Hospital Clínic of Barcelona ), Spain Con) Vance Fowler ( Duke Department of Medicine ), USA |
|||
S7-2 | Piperacillin-tazobactam for ESBL-producing Enterobacterales Pro) Jesús Rodríguez-Baño ( Hospital Universitario Virgen Macarena ), Spain Con) Patrick Harris ( The University of Queensland ), Australia |
|||
S7-3 | Combination regimen for carbapenem-resistant Acinetobacter infections Pro) Andrea L. Kwa ( Singapore General Hospital ), Singapore Con) Visanu Thamlikitkul ( Mahidol University), Thailand |
Symposium 8 | ||||
---|---|---|---|---|
09:00 - 11:00 | Gram-positive bacteria | Chair : | Paul Ananth Tambyah (Singapore), Yang Soo Kim (Korea) |
|
S8-1 | Update on antimicrobial resistance of Staphylococcus Michael Otto ( National Institute of Allergy and Infectious Diseases ), USA |
|||
S8-2 | Genomic insights into vancomycin-resistant Enterococcus faecium Glen Carter ( The University of Melbourne ), Australia |
|||
S8-3 | How to dose vancomycin: time to go Bayesian? Jennifer Le ( University of California San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences ), USA |
|||
S8-4 | Novel therapeutic approaches to bacterial infection Andrew M. Edwards ( Imperial College London ), UK |
Symposium 9 | ||||
---|---|---|---|---|
09:00 - 11:00 | Infection prevention and control | Chair : | Cheng-Hsun Chiu ( Taiwan ), Woo Joo Kim ( Korea ) |
|
S9-1 | Indoor transmission of SARS-CoV-2 Hua Qian ( Southeast University, China ), PR China |
|||
S9-2 | Infection control for COVID-19: theory and practice Kalisvar Marimuthu ( National Centre for Infectious Diseases ), Singapore |
|||
S9-3 | Environmental cleaning & disinfection: current controversies Stephan Harbarth ( Geneva University Hospital ), Switzerland |
|||
S9-4 | Outbreak control in healthcare settings Doo Ryeon Chung ( Samsung Medical Center ), Korea |
Plenary Lecture 4 | ||||
---|---|---|---|---|
11:10 - 11:50 | Chair : | Vance Fowler (USA) | ||
P-4 | The Trifecta of Diagnostic Stewardship, Antimicrobial Stewardship, and Value Assessment of New Diagnostic Tests Robin Patel ( Mayo Clinic ), USA |
Plenary Lecture 5 | ||||
---|---|---|---|---|
11:50 - 12:30 | Chair : | Robin Patel (USA) | ||
P-5 | Promoting the development of novel therapeutic agents Dennis M. Dixon ( National Institute of Allergy and Infectious Diseases ), USA |
Plenary Lecture 6 | ||||
---|---|---|---|---|
15:10 - 15:50 | Chair : | Po-Ren Hsueh (Taiwan) | ||
P-6 | Designing and conducting clinical trials that change the practice David Paterson ( University of Queensland ), Australia |
Symposium 10 | ||||
---|---|---|---|---|
15:50 - 17:20 | Fungus | Chair : | Jun Hee Woo (Korea), Jong Hee Shin (Korea) |
|
S10-1 | Epidemiology and impact of anti-fungal resistance in Asia Ban Hock Tan ( Singapore General Hospital ), Singapore |
|||
S10-2 | The confluence between viral and fungal infections Monica Slavin ( Peter MacCallum Cancer Centre ), Australia |
|||
S10-3 | Novel therapeutic options for invasive fungal infections David W. Denning ( The University of Manchester and Global Action Fund for Fungal Infections ), UK |
Symposium 11 | ||||
---|---|---|---|---|
15:50 - 17:20 | Vaccine | Chair : | Kang Won Choe (Korea), Hee Jin Cheong (Korea) | |
S11-1 | Future role of vaccines on antibacterial resistance Paul Ananth Tambyah ( National University of Singapore ), Singapore |
|||
S11-2 | Novel technologies for vaccine development Kaitlyn M. Morabito ( DMID, NIAID, NIH ), USA |
|||
S11-3 | What we learned from COVID-19 vaccination Eui-Cheol Shin ( Korea Advanced Institute of Science and Technology ), Korea |
Symposium 12 | ||||
---|---|---|---|---|
15:50 - 17:20 | HIV | Chair : | Davey Smith (USA), Sang Il Kim (Korea) |
|
S12-1 | Current Strategies for Antiretroviral Therapy Roy M. Gulick ( Weill Cornell Medicine ), USA |
|||
S12-2 | PrEP and disparities in access in the Asia Pacific Shui Shan Lee ( The Chinese University of Hong Kong ), Hong Kong, China |